Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Samer Srour, Mehrdad Abedi, Amandeep Salhotra, Edmund Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, Scott Killian, J. Scott McClellan, Nate Fernhoff, Robert Lowsky

Blood (2025) 146 (Supplement 1): 932.

https://doi.org/10.1182/blood-2025-932

Published: 2025

Journal Articles

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Blood (2025) 146 (Supplement 1): 111.

https://doi.org/10.1182/blood-2025-111

Published: 2025

Journal Articles

Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T)

Arpita Gandhi, Anna Purdum, Anna Pavlova, Ai Li, J. Scott McClellan, Bronwen Shaw, Rachel Cusatis

Blood (2025) 146 (Supplement 1): 2473.

https://doi.org/10.1182/blood-2025-2473

Published: 2025

Journal Articles

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Blood (2025) 146 (Supplement 1): 2477.

https://doi.org/10.1182/blood-2025-2477

Published: 2025

Journal Articles

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Blood (2025) 146 (Supplement 1): 6029.

https://doi.org/10.1182/blood-2025-6029

Published: 2025

Journal Articles

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Blood (2025) 145 (18): 2012–2024.

https://doi.org/10.1182/blood.2024026446

Published: 2025

Includes: Supplemental data

Journal Articles

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Mehrdad Abedi, Samer A. Srour, Amandeep Salhotra, Rasmus T. Hoeg, Edmund K. Waller, Hannah Choe, Anna Pavlova, Tamara Zharkevich, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Robert Lowsky

Blood (2024) 144 (Supplement 1): 382.

https://doi.org/10.1182/blood-2024-204256

Published: 2024

Journal Articles

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

Blood (2024) 144 (Supplement 1): 694.

https://doi.org/10.1182/blood-2024-205917

Published: 2024

Journal Articles

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Arpita Gandhi, Rasmus T. Hoeg, Sagar S. Patel, Edmund K. Waller, Jeremy M. Pantin, Caspian H. Oliai, J. Scott McClellan, Anna Pavlova, Irene Agodoa, Nathaniel B. Fernhoff, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 2230.

https://doi.org/10.1182/blood-2023-188994

Published: 2023

Journal Articles

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Caspian H. Oliai, Jeremy M. Pantin, Rasmus T. Hoeg, Lori S. Muffly, Sagar S. Patel, Arpita Gandhi, Robert Lowsky, Amandeep Salhotra, Bhagirathbhai Dholaria, Edmund K. Waller, Samer A. Srour, Anna Pavlova, Nathaniel B. Fernhoff, Irene Agodoa, J. Scott McClellan, Mehrdad Abedi, Robert S. Negrin, Everett H. Meyer

Blood (2023) 142 (Supplement 1): 230.

https://doi.org/10.1182/blood-2023-186749

Published: 2023

Journal Articles

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Samer A. Srour, Amandeep Salhotra, Robert Lowsky, Rasmus T. Hoeg, Edmund K. Waller, Anna Pavlova, J. Scott McClellan, Nathaniel B. Fernhoff, Everett H. Meyer, Mehrdad Abedi

Blood (2023) 142 (Supplement 1): 773.

https://doi.org/10.1182/blood-2023-189534

Published: 2023

Journal Articles

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Amandeep Salhotra, Samer A Srour, Rasmus T Hoeg, Ayman Saad, Everett H Meyer, Anna Pavlova, Edmund K. Waller, Mwe Mwe Chao, J Scott McClellan, Nathaniel B Fernhoff, Robert Lowsky, Mehrdad Abedi

Blood (2022) 140 (Supplement 1): 1865–1866.

https://doi.org/10.1182/blood-2022-170459

Published: 2022

Journal Articles

Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Everett H Meyer, M Scott Killian, Anna Pavlova, Cameron Bader, Sean Summers, Fernando Teque, J Scott McClellan, Nathaniel B Fernhoff

Blood (2022) 140 (Supplement 1): 7656–7657.

https://doi.org/10.1182/blood-2022-164468

Published: 2022

Journal Articles

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Blood (2022) 140 (Supplement 1): 654–656.

https://doi.org/10.1182/blood-2022-165654

Published: 2022

Journal Articles

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Blood (2021) 138 (Supplement 1): 98.

https://doi.org/10.1182/blood-2021-154191

Published: 2021

Journal Articles

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors

Arpita Gandhi, Anna Moroz, Lori Muffly, Parveen Shiraz, Levanto Schachter, Nathaniel B Fernhoff, J Scott McClellan, Robert S. Negrin, Jason Gotlib, Everett H Meyer

Blood (2021) 138 (Supplement 1): 1819.

https://doi.org/10.1182/blood-2021-150521

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Preliminary safety and efficacy of myeloablative orca-q with tacrolimus or without graft-versus-host disease prophylaxis for treatment of advanced hematologic malignancies

Allogeneic HSC and regulatory T cell (Orca-T) engineered cell therapy following reduced intensity conditioning: Results of a single center Phase 1 study

Orca-T demonstrates favorable quality of life and healthcare resource use compared to standard allohsct plus tac/MTX for GVHD prevention in a randomized Phase 3 clinical trial (Precision-T)

Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial

Observational comparison of orca-T to registry-based post-transplant cyclophosphamide patients using matched unrelated donors

Donor regulatory T-cell therapy to prevent graft-versus-host disease

Preliminary Safety and Efficacy of Myeloablative Orca-Q with No GvHD Prophylaxis for Treatment of Advanced Hematologic Malignancies

Observational Comparison of Overall Survival between Phase 1b Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients

High Disease-Free Survival in Patients with High-Risk MDS Treated with Orca-T

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic Malignancies

Safety and Efficacy of Orca-Q with Haploidentical Donors for the Treatment of Advanced Hematologic Malignancies without the Use of Post-Transplant Cyclophosphamide

Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide

Rapid Immune Reconstitution and Elevated Regulatory T Cell Frequencies in Patients Treated with Orca-T

Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study

Outcomes for Myelofibrosis Patients Following Myeloablative Allogeneic Stem Cell Transplantation Using the Orca-T Graft from HLA-Matched Related and Unrelated Donors

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only